发布求助
文献互助 智能选刊 最新文献

The Brown University Psychopharmacology Update最新文献

筛选
英文 中文
Heatwaves exacerbate risk of illnesses in patients with mental health conditions 热浪加剧了精神疾病患者患病的风险
The Brown University Psychopharmacology Update Pub Date : 2025-06-02 DOI: 10.1002/pu.31326
{"title":"Heatwaves exacerbate risk of illnesses in patients with mental health conditions","authors":"","doi":"10.1002/pu.31326","DOIUrl":"https://doi.org/10.1002/pu.31326","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 7","pages":"6-8"},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Review of GLP-1 trials finds low incidence of suicide risk 对GLP-1试验的回顾发现自杀风险发生率低
The Brown University Psychopharmacology Update Pub Date : 2025-06-02 DOI: 10.1002/pu.31321
{"title":"Review of GLP-1 trials finds low incidence of suicide risk","authors":"","doi":"10.1002/pu.31321","DOIUrl":"https://doi.org/10.1002/pu.31321","url":null,"abstract":"<p>A systematic review and meta-analysis comprising 27 trials comparing glucagon-like peptide 1 (GLP-1) receptor agonists and placebo in patients with type 2 diabetes or obesity found no significantly increased risk of suicidal behavior in conjunction with the popular medications. The incidence of suicide and self-harm was very low in both the GLP-1 and placebo groups. Results of the review were published online March 19, 2025, in <i>JAMA Psychiatry</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 7","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Greater anticholinergic burden associated with poorer cognition in patients with psychosis 精神病患者抗胆碱能负担加重与认知能力下降相关
The Brown University Psychopharmacology Update Pub Date : 2025-06-02 DOI: 10.1002/pu.31325
{"title":"Greater anticholinergic burden associated with poorer cognition in patients with psychosis","authors":"","doi":"10.1002/pu.31325","DOIUrl":"https://doi.org/10.1002/pu.31325","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144190861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quetiapine augmentation more effective than lithium in treatment-resistant depression trial 在难治性抑郁症试验中，喹硫平增强比锂更有效
The Brown University Psychopharmacology Update Pub Date : 2025-06-02 DOI: 10.1002/pu.31328
{"title":"Quetiapine augmentation more effective than lithium in treatment-resistant depression trial","authors":"","doi":"10.1002/pu.31328","DOIUrl":"https://doi.org/10.1002/pu.31328","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world usage of paliperidone palmitate injection 棕榈酸帕利哌酮注射液的实际用法
The Brown University Psychopharmacology Update Pub Date : 2025-06-02 DOI: 10.1002/pu.31322
Y. W. Francis Lam Pharm.D., FCCP
{"title":"Real-world usage of paliperidone palmitate injection","authors":"Y. W. Francis Lam Pharm.D., FCCP","doi":"10.1002/pu.31322","DOIUrl":"https://doi.org/10.1002/pu.31322","url":null,"abstract":"<p>A challenge in achieving clinical remission in patients with schizophrenia lies in the high rate of antipsychotic discontinuation, often resulting in relapse, characterized by exacerbation of symptomatology, deterioration in functional activities, and the emergence of treatment resistance. Long-acting antipsychotics have been developed to help reduce medication nonadherence and minimize relapse. One of the most widely used of these drugs is paliperidone palmitate, a long-acting injectable (LAI) formulation of paliperidone (an active metabolite of risperidone).</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study documents risk of thyroid, kidney complications from lithium treatment 研究记录了锂治疗的甲状腺和肾脏并发症的风险
The Brown University Psychopharmacology Update Pub Date : 2025-06-02 DOI: 10.1002/pu.31329
{"title":"Study documents risk of thyroid, kidney complications from lithium treatment","authors":"","doi":"10.1002/pu.31329","DOIUrl":"https://doi.org/10.1002/pu.31329","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Data on prescription stimulant misuse suggest need for closer screening 关于处方兴奋剂滥用的数据表明需要进行更密切的筛查
The Brown University Psychopharmacology Update Pub Date : 2025-06-02 DOI: 10.1002/pu.31323
{"title":"Data on prescription stimulant misuse suggest need for closer screening","authors":"","doi":"10.1002/pu.31323","DOIUrl":"https://doi.org/10.1002/pu.31323","url":null,"abstract":"<p>Among U.S. adults aged 18 to 64 who reported using prescription stimulant medications, around one-quarter reported stimulant misuse and 9% reported stimulant use disorder, according to a new study. Stimulant misuse and stimulant use disorder were substantially more common among individuals using amphetamines than among those using methylphenidate.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Your Medication Information 您的用药信息
The Brown University Psychopharmacology Update Pub Date : 2025-06-02 DOI: 10.1002/pu.31330
{"title":"Your Medication Information","authors":"","doi":"10.1002/pu.31330","DOIUrl":"https://doi.org/10.1002/pu.31330","url":null,"abstract":"<p>Venlafaxine extended release (generic) Effexor XR (brand)</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 7","pages":"9-10"},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study shows improved schizophrenia negative symptoms with xanomeline-trospium 研究表明使用异丙胺-trospium可改善精神分裂症阴性症状
The Brown University Psychopharmacology Update Pub Date : 2025-04-29 DOI: 10.1002/pu.31318
{"title":"Study shows improved schizophrenia negative symptoms with xanomeline-trospium","authors":"","doi":"10.1002/pu.31318","DOIUrl":"https://doi.org/10.1002/pu.31318","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 6","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143884183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Weekly semaglutide reduces craving in adults with alcohol use disorder 每周服用西马鲁肽可减少成人酒精使用障碍患者的渴求
The Brown University Psychopharmacology Update Pub Date : 2025-04-29 DOI: 10.1002/pu.31307
{"title":"Weekly semaglutide reduces craving in adults with alcohol use disorder","authors":"","doi":"10.1002/pu.31307","DOIUrl":"https://doi.org/10.1002/pu.31307","url":null,"abstract":"<p>Weekly doses of the glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide resulted in reduced alcohol craving relative to placebo in adults with alcohol use disorder (AUD), a 9-week randomized trial has found. Use of semaglutide also resulted in improvement in some but not all alcohol use outcomes compared with placebo. Study results were published online Feb. 12. 2025, in <i>JAMA Psychiatry</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 6","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143884141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信